Apnimed has filed for an initial public offering after years of delay, as the company moves forward while the FDA reviews its sleep apnea program. The report describes the Nasdaq move following a period of milestone seeking and positions the IPO as a funding catalyst while regulatory review continues. For investors and biotech operators, IPO timing here is tightly coupled to the near-term regulatory calendar—any FDA decision can quickly change valuation and runway. Companies with a single late-stage regulatory catalyst frequently face high volatility around filing progress and review outcomes, especially for airway and sleep disorders where endpoints and comparator choices can drive decisions.